Daniel P. Petrylak, MD, presented “The Use of Antibody-drug Conjugates in Treating Advanced Urothelial Cancer” at the 6th International Bladder Cancer Update on November 20, 2022, in Scottsdale, Arizona.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Petrylak, Daniel P. “The Use of Antibody-drug Conjugates in Treating Advanced Urothelial Cancer.” November 2022. Accessed Aug 2024. https://grandroundsinurology.com/the-use-of-antibody-drug-conjugates-in-treating-advanced-urothelial-cancer/
The Use of Antibody-drug Conjugates in Treating Advanced Urothelial Cancer – Summary
Dr. Daniel P. Petrylak provides an in-depth exploration of how ADCs are revolutionizing cancer therapy by combining the targeting capability of monoclonal antibodies with the potent cytotoxic effects of chemotherapy.
Dr. Petrylak begins by explaining the fundamental principles behind ADCs, highlighting their design to specifically target cancer cells while minimizing damage to healthy tissues. He elaborates on the mechanism of action, where the antibody component binds to a specific antigen on the cancer cell surface, delivering the attached cytotoxic drug directly into the cancer cell. This targeted delivery enhances the effectiveness of the treatment while reducing systemic toxicity.
Focusing on the clinical application of ADCs in advanced urothelial cancer, Dr. Petrylak presents data from recent clinical trials that showcase their efficacy and safety. He emphasizes significant improvements in patient outcomes, including increased response rates and prolonged survival, particularly in patients who have previously failed standard therapies. Dr. Petrylak discusses specific ADCs that have shown promise in this setting, providing detailed insights into their development, clinical trial results, and approval status.
About the 6th International Bladder Cancer Update:
The International Bladder Cancer Update (IBCU) is a CME conference focused on the diagnosis and treatment of bladder cancer. The conference offers medical professionals an opportunity to listen to updates from, and interact with, expert international faculty to improve knowledge and determine best treatment practices to improve patient outcomes. IBCU encompasses expert lectures, interactive discussions, a panel roundtable, debates, and case presentations. It is physician-led, multi-supported, and designed for urologists, urologic oncologists, and other healthcare professionals involved in the treatment of bladder cancer.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Daniel P. Petrylak, MD, leads the genitourinary cancers medical oncology team at Smilow Cancer Hospital as director of the genitourinary cancer research group, professor, and co-director of the Cancer Signaling Network program. Dr. Petrylak joined Yale from Herbert Irving Cancer Center at Columbia University Medical Center with New York-Presbyterian Hospital, where he served as Professor of Medicine (Medical Oncology) and Urology and began his appointment in September of 2012. After serving for more than 20 years as the advanced bladder chair for SWOG, Dr. Petrylak is now the Vice Chair of the Genitourinary Committee.
